Jeffrey Brummer, DO
Family Medicine · Effingham, ILNPI 1265417851
Payments from drug & device makers
Across 106 payments — averaging $24.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Organogenesis Inc.$697
- Kerecis Limited$166
- Amgen$159
- AbbVie$151
- Novo Nordisk$134
- Tactile Systems Technology Inc$128
- plus $1K from 26 others
What the payments were for
- Food & beverage$2,605100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Organogenesis Inc. | 33 | $697 |
| Kerecis Limited | 2 | $166 |
| Amgen | 4 | $159 |
| AbbVie(2 entities) | 8 | $151 |
| Novo Nordisk | 7 | $134 |
| Tactile Systems Technology Inc | 3 | $128 |
| Osiris Therapeutics Inc. | 1 | $120 |
| Smith+Nephew | 6 | $120 |
| Next Science LLC | 1 | $114 |
| Musculoskeletal Transplant Foundation Inc. | 1 | $88 |
| Merck | 4 | $85 |
| Pfizer | 5 | $78 |
| Medtronic(2 entities) | 2 | $75 |
| Phathom Pharmaceuticals, Inc. | 3 | $62 |
| Ironshore Pharmaceuticals Inc. | 3 | $51 |
| Lilly USA, LLC | 3 | $47 |
| Acadia Pharmaceuticals Inc | 3 | $44 |
| Solventum Corporation | 2 | $35 |
| Paratek Pharmaceuticals, Inc. | 2 | $29 |
| Viatris Specialty LLC | 1 | $24 |
| Xeris Pharmaceuticals, Inc. | 1 | $22 |
| Lundbeck LLC | 1 | $21 |
| Novartis | 1 | $20 |
| Sanofi-aventis U.S. LLC | 1 | $20 |
| Otsuka America Pharmaceutical, Inc. | 1 | $19 |
| Sanofi Pasteur Inc. | 1 | $19 |
| Seqirus USA Inc | 1 | $18 |
| GSK | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $16 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
| Johnson & Johnson | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Kerecis Omega3 Marigen$615
- Kerecis Omega3 SurgiClose$154
- PURAPLY WOUND MATRIX$138
- Stravix$120
- Grafix$120
- GrafixPL$120
- Repatha$119
- PuraPly$115
- SurgX$114
- Xperience$114
- BlastX$114
- FLEXITOUCH$101
- ACTITOUCH$101
- ENTRE$101
How this compares
$2,617 in reported general payments places this provider in the 85th percentile of 4,116 family medicine providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 150 | $93,954 |
| JanuviaSitagliptin Phosphate | 74 | $73,077 |
| XareltoRivaroxaban | 85 | $72,043 |
| OzempicSemaglutide | 47 | $55,287 |
| TrulicityDulaglutide | 45 | $49,278 |
| MounjaroTirzepatide | 28 | $33,460 |
| Breo ElliptaFluticasone/Vilanterol | 56 | $30,336 |
| JardianceEmpagliflozin | 15 | $18,947 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 20 | $13,508 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 28 | $12,023 |
| LantusInsulin Glargine,hum.Rec.Anlog | 43 | $6,621 |
| Tresiba Flextouch U-100Insulin Degludec | 12 | $6,007 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $5,196 |
| GemtesaVibegron | 21 | $5,010 |
| Levothyroxine Sodium | 636 | $4,918 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $78 | $93,954150 claims |
| Lilly USA, LLCTrulicity, Mounjaro, Olanzapine | $47 | $84,036119 claims |
| MerckJanuvia | $85 | $73,07774 claims |
| Johnson & JohnsonXarelto | $14 | $72,04385 claims |
| Novo NordiskOzempic | $134 | $55,28747 claims |
| GSKBreo Ellipta, Trelegy Ellipta | $16 | $43,84476 claims |
| Sanofi-aventis U.S. LLCLantus | $20 | $6,62143 claims |
| AbbVieSynthroid | $151 | $1,85027 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 4,116 family medicine providers in Illinois.
Other family medicine in Effingham
- Douglas KabbesEffingham$49K
- Daniel BruneCreve Coeur$15M
- Ali BajwaSpringfield$5.8M
- John ElsenEvergreen Park$5M
- Manohar JethaniBerwyn$4.9M
- Tiffany NguyenSkokie$3.9M
- Bradley TorphyChicago$3M
- Diana WidicusRochester$2.6M
- Nicholas WeberEureka$2.5M
- Stanley KochMorton$2.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.